Lilly Inks Deal with Innovent to Speed Up Early Drug Development

Eli Lilly & Co. is paying $350 million upfront to collaborate with Chinese biotech Innovent Biologics Inc. in developing new treatments for cancer and immune disorders, a further vote of...

By Amber Tong · Bloomberg

Eli Lilly & Co. is paying $350 million upfront to collaborate with Chinese biotech Innovent Biologics Inc. in developing new treatments for cancer and immune disorders, a further vote of confidence for the innovation capabilities of the country’s drugmakers.